Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity for biosimilars developers. The pipeline of immune biosimilars includes several agents that reference AbbVie’s very successful biologic Humira (adalimumab). Biosimilars of Humira have been available in Europe since October 2018. Biosimilars referencing Roche’s Rituxan / MabThera (rituximab) have also launched in Europe and in the United States. As the immune biosimilars space becomes increasingly competitive, it is important that manufacturers and marketers of biosimilars and branded biologics understand the factors that most influence physicians’ choice of therapy. Decision Resources Group conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights into their attitude toward biosimilars, the drivers of and barriers to their use of biosimilars, and their expectations for future biosimilar adoption.
- Have physicians received recommendations to use biosimilars?
- Are physicians switching patients from reference brands to biosimilars?
- What factors do physicians consider when choosing between competing biosimilars?
- How are TNF-alpha inhibitor and MAb biosimilars performing, and what are physicians’ expectations for their future uptake?
- What are the key drivers of and barriers to the uptake of TNF-alpha inhibitors and MAb biosimilars?
- Markets covered: France, Germany, and the United States.
- Primary research: Survey of 91 rheumatologists and 92 gastroenterologists.
Key companies mentioned:
- Johnson & Johnson / Janssen
- Merck & Co. / MSD
- Novartis / Sandoz
- Pfizer / Hospira
- Roche / Genentech
- Samsung Bioepis
Key drugs mentioned:
- Inflectra (infliximab)
- Remsima (infliximab)
- Benepali (etanercept)
- Flixabi (infliximab)
- Truxima (rituximab)
- Enbrel (etanercept)
- Humira (adalimumab)
- Remicade (infliximab)
- Rituxan / MabThera (rituximab)
- Simponi (golimumab)
- Cimzia (certolizumab pegol)
- Orencia (abatacept)
- Actemra / RoActemra (tocilizumab)
- Stelara (ustekinumab)
- Entyvio (vedolizumab)
- Biosimilars - Current Treatment - Immunology
Author(s): Qinghui Yu
Marta Delgado, Ph.D. is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a Ph.D. in Molecular Neuroscience from University College of London (UCL) and a B.Sc. in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.